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1. ABSTRACT 
 
The role of EGFR in cancer development and 
progression has been recognized for long time in a variety 
of human malignancies including lung, head and neck, 
colon, breast, ovary and glioma. Recently its role as a target 
of antineoplastic agents has also been identified and a 
variety of EGFR-targeted drugs is already being used in a 
clinical setting and others are at present under 
investigation.  Many data involving EGFR protein 
expression are now available for the choice of anti-EGFR 
monoclonal antibodies in colorectal cancer and with regard 
to EGFR gene mutations for the choice of tyrosine kinase 
inhibitors in lung cancer. Other EGFR-related molecular 
factors, including the EGFR gene copy number, are 
currently under investigation. This review summarizes both 
preclinical and clinical available data regarding EGFR 
genomic alterations as prognostic and predictive factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. INTRODUCTION 
 
The epidermal growth factor receptor (EGFR) and 
members of its family are important targets for cancer 
treatment due to their ability to stimulate cell proliferation, 
survival and migration in normal and cancerous cells (1). 
The EGFR gene is located on chromosome 7p12-13 and 
encodes a tyrosine kinase receptor composed of four 
functional domains: an extra-cellular cysteine-rich ligand-
binding domain, which can be further divided into four 
additional sub-domains (EGFR-I, EGFR-II, EGFR-III, 
EGFR-IV); a trans-membrane domain; an intracellular 
tyrosine kinase (TK) domain and a C-terminal domain 
which functions as a regulator (2). The binding of the 
epidermal growth factor (EGF) or other ligands, such as 
betacellulin, epiregulin, TGF-α, amphiregulin, and heparin-
binding EGF-like growth factor (HB-EGF), to the 
extracellular domain, induces homodimerization of two 
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Table 1. The most important studies about correlation of EGFR protein expression and efficacy of anti-EGFR drugs 
Study Phase Tumor No. of 
patients 
Treatment Results 
Saltz LB, et al. 
J Clin Oncol 2004 (8) 
II CRC 57 Cetuximab No correlation of response rate with EGFR expression 
levels 
Cunningham D, et al. 
N Engl J Med 2004 (10) 
II 
(randomized) 
CRC 474 Cetuximab + irinotecan 
Vs Cetuximab alone 
No correlation of response rate with EGFR expression 
levels 
Lenz HJ, et al. 
J Clin Oncol 2006 (9) 
II CRC 346 Cetuximab No correlation of response rate with EGFR expression 
levels 
Berlin J, et al. 
Clin Colorectal Cancer 
2007 (12) 
II CRC 43 Panitumumab + IFL or 
FOLFIRI 
No correlation of response rate with EGFR expression 
levels 
Hecht JR, et al. 
Clin Cancer Res 2010 
(13) 
II CRC 388 Panitumumab Clinical responses found also in patients with negative 
EGFR 
Douillard JY, et al. 
J Clin Oncol 2010 (17) 
III NSCLC 380 Gefitinib vs docetaxel No predictive role of EGFR protein expression 
Herbst RS, et al. 
J Clin Oncol 2005 (20) 
III NSCLC 1079 Erlotinib vs placebo No correlation between EGFR expression levels and 
clinical outcomes 
Tsao MS, et al. 
N Engl J Med 2005 (27) 
III NSCLC 325 Erlotinib vs placebo Correlation of EGFR protein expression with an 
objective response 
Hirsch FR, et al. 
J Clin Oncol 2006 (28) 
III NSCLC 379 Gefitinib vs placebo Correlation of EGFR protein expression with clinical 
outcomes 
 
EGFRs or heterodimerization of EGFR with other members 
of its family, particularly with HER2. In this way the 
tyrosine kinase domain becomes active, causing the auto-
phosphorylation of C-terminal domain (3). The 
phosphorylated tyrosine residues are the binding sites for 
adapter proteins and this activates different pathways, 
including that of MAPK, PI3K and STAT3/5 (4). This 
explains how EGFR overexpression or aberrant activation 
induces proliferation, invasion and metastatization, all 
mechanisms associated with tumor phenotype.  
 
Since EGFR is involved in a variety of human 
cancers, including those involving the lung, head and neck, 
colon, breast and ovary and also gliomas (5), and has been 
linked to poorer outcomes (6), EGFR inhibitors have 
improved the range of treatments for various solid tumors. 
Different clinical studies have been conducted with these 
agents alone or in combination with other anticancer drugs 
and it has been seen that their action depends not only on 
tumor type but also on other factors, such as EGFR gene 
alterations. In the light of the evidence which has emerged 
in recent years, the aim of this review is to find out whether 
EGFR protein expression, mutation status and gene copy 
number can be considered as predictive and prognostic 
biomarkers for the efficacy of EGFR target therapy, in 
particular with regard to anti-EGFR monoclonal antibodies 
and tyrosine kinase inhibitors (TKI). 
 
3. EGFR PROTEIN EXPRESSION  
 
EGFR expression and cancer prognosis have 
been investigated in several types of human cancers and 
although there are some conflicting results, patients with 
EGFR over-espression tend to have poor prognosis. The 
tissue expression of the EGFR protein is estimated between 
60 and 85% in colorectal cancer (CRC). Its increased 
expression seems to be correlated with a higher stage, 
aggressiveness, presence of metastases and poorer 
prognosis.  In the first clinical studies with anti-EGFR 
monoclonal antibodies, only patients affected by mCRC
 
expressing EGFR protein were included. This limitation 
derived from the supposition that these agents could be 
effective only when their target is present in cancer cells. 
Subsequently retrospective analysis of these clinical trials 
suggested a less clear role of EGFR positivity for the 
prediction of the response to these monoclonal antibodies. 
In fact, patients with EGFR-negative mCRC also showed 
benefit from this treatment (7) (Table 1). 
 
Three different clinical trials have evaluated the 
relationship between the response rates in patients treated 
with anti-EGFR monoclonal antibodies and the EGFR 
tissue expression levels tested by immunohistochemistry 
(IHC) and no correlation was found in any of these studies 
(8-10) (Figure 1). 
 
Both objective response and stable disease rates 
in EGFR-negative cases appeared similar to EGFR-positive 
patients (9, 11) and these results were confirmed in mCRC 
patients treated with panitumumab (12, 13). Several studies 
have shown that there is no significant correlation between 
EGFR expression by IHC and efficacy of TKIs even in 
NSCLC patients (14-26). Two clinical trials comparing 
erlotinib and gefitinib with a placebo for non–small-cell 
lung cancer both demonstrated a survival benefit (26, 27), 
while phase II studies and three other phase III randomized 
studies (16, 19, 28) did not find a significant relationship 
(Table 1). Thus, EGFR protein expression cannot be 
considered as a useful biomarker of activity for anti-EGFR 
TKIs. Some authors have attempted to explain these 
findings (7, 29). They found possible reasons in the 
biological and technical problems related to the limitations 
and nonquantitative nature of conventional IHC. 
 
The following limits of IHC have been 
recognized for some considerable time: 
 
− malignant cells of a tumor are heterogeneous, so 
the EGFR expression is variable within a neoplastic mass.
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Figure 1. Differences of response rates to Cetuximab 
according to the EGFR staining intensity (A) and the 
percentage of the EGFR expressing cells (B). 
 
 − EGFR protein includes both high and low affinity 
binding domains. Only the high affinity domains, which are 
usually poorly expressed, exert an effective biological 
function. The authors supposed that IHC could not be 
sensitive enough to recognize the high affinity binding 
sites. IHC allows the overall evaluation of EGFR protein, 
but is not able to distinguish the various receptor types with 
different biological activity 
 
− the IHC-applying laboratories use different 
methods regarding the management of the specimens, and 
involving the tests and data reporting. 
 
− the primitive site of the tumor and its metastases 
seem to express the EGFR protein differently. 
 
At present, an effective scoring system and clear guidelines 
involving the standardization of EGFR protein evaluation 
by IHC are required. 
 
4. EGFR MUTATIONS IN THE TYROSINE KINASE 
DOMAIN 
 
EGFR mutations in the tyrosine kinase domain 
have been classified “as activating mutations” because they 
are all responsible for a ligand-independent activation of 
TK activity. Such mutations have been found in lung 
adenocarcinoma and more frequently among East Asian 
female patients with this type of cancer but without a 
smoking history (30, 31). The genomic region most 
affected by TK domain mutations is between exons 18 and 
21 and the majority of EGFR mutations are deletions in 
exon 19 (over 20 variant types) and point mutation which 
substitutes an arginine with a leucine at codon 858 (L858R) 
in exon 21 (30). As minor EGFR mutations, there have also 
been reports of mutations at codon 719 (exon 18), 765 and 
783 (exon 20) and in-frame insertion mutations in exon 20.  
Activating mutations have been found to confer sensitivity 
to the TKIs gefitinib and erlotinib (31-33) as the 
compromised ATP affinity of the EGFR mutants renders 
them susceptible to inhibition (34, 35). In fact, for patients 
harboring those mutations in the TK domain of EGFR, the 
response rate with erlotinib and gefitinib is approximately 
70% (36, 37).  Several reports have suggested that patients 
with exon 19 deletions have a longer PSF and overall 
survival compare to those with the L858R mutation after 
treatment with erlotinib and gefitinib (38, 39). Furthermore, 
no significant differences in response rate, median PFS and 
survival between the two TKIs have been observed (40). 
The INTEREST study has shown gefitinib to be a valid 
treatment option for patients with pretreated advanced non-
small-cell lung cancer, proving to be non-inferior in overall 
survival and similar in tumor response and progression-free 
survival to docetaxel (41). 
 
The IPASS trial compared first-line gefitinib 
with carboplatin/paclitaxel in Asian patients with advanced 
NSCLC and with no history of substantial smoking. 
Patients harboring EGFR mutations had a significantly 
longer PFS with gefitinib (HR, 0.48; P<0.001), whereas 
those with wild-type EGFR had a better PFS with 
chemotherapy (HR, 2.85; P<0.001) (42). Not all tumors 
having activating mutations are associated with greater 
response to treatment with gefitinib and erlotinib; their 
clinical efficacy is limited by the development of acquired 
drug resistance such as mutation of the substitution of 
threonine 790 with methionine (T790M), which has been 
detected in 50% of clinically resistant patients (43, 44) and 
has been associated with a short PFS (7.7 months in 
patients with the T790M mutation and 16.5 months in those 
without the mutation) (45). Nevertheless, the T790M 
mutant remains sensitive to irreversible inhibitors, such as 
EKB-569 and HKI-272 (43, 46, 47). In vitro studies have 
shown that EGFR T790M restores the affinity for ATP to 
the same levels of WT EGFR (48).  In NIH 3T3 cells the 
T790M with the L858R mutant increases EGFR activity 
and enhances the transformed phenotype (49) and 
transgenic mice expressing T790M mutant develop lung 
adenocarcinomas (50), although with a longer latency than 
those harboring the L858R or combined L858R and T790M 
mutations (51, 52). 
 
The T790M mutation has also been detected in a 
small fraction of tumor cells before drug treatment, 
supporting the idea that tumor cells harboring this mutation 
might be present from the beginning of the treatment with 
gefitinib or erlotinib and be enriched over time (52). 
Genetic heterogeneity of tumors is an issue to be 
considered when interpreting EGFR mutation data. In 
recent years, it has been suggested that, in order to detect a 
small fraction of mutant alleles among a large number of 
wild-type alleles in clinical samples, it is advisable to use a 
sensitive assay, such as SARMS technology, rather than 
direct DNA sequencing (53). Contrary to what was 
observed in non-small lung cancer, mutations in the 
catalytic domain of EGFR are rare in CRC, suggesting that 
gefitinib is unlikely to be effective in patients with these 
tumors (54-56). 
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5. EGFR MUTATIONS IN THE EXTRACELLULAR 
DOMAIN 
 
In the extracellular domain of EGFR, three 
different types of deletions have been found, defined as 
EGFR variant I, II and III (EGFR vI, EGFR vII and EGFR 
vIII).  The most common of the three mutants found in 
human cancer is EGFRvIII, consisting of in-frame deletion 
from exons 2 through 7 (amino acids 6–273) in the 
extracellular domain, resulting in ligand-independent 
constitutive activation of EGFR (57). This mutation has not 
been observed in normal tissue (58) and is expressed in a 
number of cancers, including breast cancer, ovarian cancer, 
prostate cancer, and lung cancer (58) most notably 
glioblastoma (59-61), where it is reported to occur at a 
frequency of 20%-30% and in 50%-60% of tumors the 
amplification of wt EGFR is observed (62, 63).  
In glioblastoma cell lines, EGFRvIII confers resistance to 
gefitinib with constitutive activation of EGFR and 
persistence of phospho-Akt (64). In lung cancer, contrary to 
the other deletions and mutations of EGFR, EGFRvIII 
expression is relatively resistant to gefitinib and erlotinib 
and more sensitive to treatment with irreversible EGFR 
TKIs such as HKI-272 (65). In mCRC this variant is rare 
and does not play an important role (66). 
 
6. EGFR GENE COPY NUMBER  
 
Amplification or high polysomy of EGFR have 
been detected in a variety of solid malignant tumors, and 
have been associated with poor prognosis (67). In NSCLC, 
the gene copy number appears to be a promising biomarker 
for predicting a survival benefit with EGFR-TKI therapy in 
both second line, (68) and third line clinical trials (26, 27) 
and is more predictive of patient survival after gefitinib 
treatment than EGFR mutations (69). However, the 
predictive value of EGFR gene amplification for TKI 
sensitivity has proved to be lower in Japanese cohorts than 
in Western NSCLC cohorts. These findings suggest a 
possible difference mechanism of EGFR pathway 
activation in NSCLC between Asian and Caucasian 
populations (70, 71). A high EGFR copy number is 
frequently correlated with EGFR somatic mutations, (72-
77) although, since it is difficult to obtain sufficient 
amounts of tumor tissue for genetic analysis from patients 
with advanced NSCLC, the relationship between these two 
types of EGFR alterations has remained unclear. In CRC, 
discrepant results have emerged from recent studies. As 
emerged from two large studies, the percentage of CRC 
with increased EGFR copy number is probably only 10% to 
15% of tumors (29, 78) but despite the low incidence it 
seems to be an interesting predictor of response to anti-
EGFR (55, 79, 80). Contrary to these authors, Lenz et al. 
(9) showed a positive relationship between increased EGFR 
gene copy number (determined by quantitative PCR) and 
OS of patients, but not with PFS or response to cetuximab. 
Finally Khambata-Ford S et al, did not find any correlation 
between increased EGFR copy number and response to 
cetuximab (81).  So we need further data to conclude about 
its applicability in clinical practice for decision making of 
anti-EGFR monoclonal antibodies.  
 
7. PERSPECTIVE 
 
The EGFR-related pathway is recognized as one 
of the main molecular mediators of tumor development and 
progression. When this pathway becomes abnormally 
activated, tumor cells acquire independence from mitogenic 
extracellular signals. Constitutive activation of the EGFR 
pathway induces prognostic worsening. For this reason, 
some researchers have developed new molecules to target 
both the extracellular and the intracellular domain of the 
EGFR. Since the cost of these agents is often higher than 
conventional chemotherapeutic drugs, research is 
continually underway in order to discover predictive factors 
leading to the clearer identification of potential responders. 
 
At the present time, the anti-EGFR monoclonal 
antibodies, cetuximab and panitumumab, are frequently 
used in advanced colorectal cancer management. EGFR 
protein expression by IHC was initially considered a 
mandatory requirement to deliver these drugs but later 
some authors have highlighted the absence of relationship 
between EGFR expression and clinical response in these 
patients. To date others parameters are required for the 
selection of patients to be treated with these monoclonal 
antibodies. The EGFR gene copy number and mutations 
have not proved to have any role as predictive factors in 
this setting of patients. KRAS and BRAF mutation testing 
has now become fundamental to assess responsiveness in 
colorectal cancer patients. 
Activating mutations in the EGFR intracellular domain are 
however, related to the clinical response to EGFR TKIs, 
gefitinib and erlotinib, in patients with advanced NSCLC. 
Other genomic alterations of EGFR, even in other 
malignancies, have been identified through various 
preclinical studies, although they have not yet been applied 
in clinical practice. Further clinical investigations are 
needed to clarify the relationship between genomic changes 
and therapeutic efficacy. 
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